Truist Financial Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its target price decreased by investment analysts at Truist Financial from $120.00 to $95.00 in a report issued on Thursday, Marketbeat.com reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price target indicates a potential upside of 24.61% from the stock’s previous close.

Several other brokerages have also commented on BSX. Canaccord Genuity Group decreased their price objective on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday, January 15th. Royal Bank Of Canada boosted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Barclays cut their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Robert W. Baird lowered their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $109.43.

Boston Scientific Stock Down 1.8%

Boston Scientific stock opened at $76.24 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The stock has a market capitalization of $113.02 billion, a price-to-earnings ratio of 39.30, a PEG ratio of 1.37 and a beta of 0.67. Boston Scientific has a 1-year low of $74.86 and a 1-year high of $109.50. The business has a fifty day moving average price of $93.39 and a 200-day moving average price of $98.79.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the company posted $0.70 EPS. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Hedge funds have recently added to or reduced their stakes in the company. Riverwater Partners LLC boosted its stake in shares of Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after acquiring an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management increased its stake in shares of Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 99 shares in the last quarter. Crown Wealth Group LLC raised its holdings in Boston Scientific by 4.7% in the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares during the period. Claret Asset Management Corp grew its holdings in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 102 shares during the period. Finally, Sound View Wealth Advisors Group LLC grew its holdings in Boston Scientific by 3.9% in the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 103 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.